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Persistence of the otoprotective effect. How long does 
otoprotection against amikacin lasts?
Abstract
Andreia Ardevino de Oliveira1, Matheus de Souza Campos2, Adriana de Andrade Batista Murashima3, 
Maria Rossato4, Miguel Angelo Hyppolito5, José Antônio Apparecido de Oliveira6
There is evidence that a “resistance phenomenon” occurs when a none-damaging dose of amikacin 
protects the hair cells from ototoxicity. Our goal is to prove that this resistance is persistent.
Method: Experimental study - 14 albino guinea pigs (Cavia porcellus) divided into three groups. 
The auditory function was assessed by distortion product otoacoustic emissions (DPOAE): before 
exposure to amikacin, on the 15th day after the non-damaging dose was injected, at the end of the 
damage dose injection and prior to decapitation.
Results: Group A (control) presented normal hearing and histological pattern. Group B (amikacin 
20 mg/kg/day (IM) for 30 days and affecting dose (400 mg/kg/day) for 12 days and Group C (same 
protocol of Group B, but kept for 60 days and slaughtered), the DPOAE confirmed normal auditory 
function in the pre-exposure and maintenance of the standard-dose; however, significant loss of 
auditory function after the end of the damaging dose injection.
Conclusion: The protection phenomenon did not extended for a period of 30 to 60 days after the 
application of damaging doses of amykacin.
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INTRODUCTION
Aminoglycosides are among the most used antibiotic 
agents in the world because of their high efficacy and low 
cost. Nonetheless, they do have important side effects, 
such as kidney toxicity and ototoxicity.
The ototoxic action of these antibiotics happen 
directly on the polyphosphoinositides receptors, located 
on the membrane of hair cells of the organ of Corti, of the 
saccular and utricular macula and the ampullary crests of 
the vestibular system. These receptors are lipidic compo-
nents of the cell membrane which form complexes with 
aminoglycosides, bringing about changes to the membrane 
permeability, which may cause cellular failure with con-
sequent hearing loss1.
The ototoxicity mechanism against the hair cells in-
volves the capture of these aminoglycosides by these cells, 
through receptor-mediated endocytosis2, individual genetic 
predisposition to cell damage involving mitochondrial 
DNA alterations3,4, the damage action of Reactive Oxygen 
Species (ROS) - formed as a consequence of aminoglyco-
sides scavenging iron5,6 - all the way to programmed cell 
death by apoptosis7.
Ototoxicity may appear during acute or late expo-
sure to aminoglycosides, even months after the exposure. 
It may evolve to a more severe degree or even recovery of 
normal auditory thresholds (prior to the exposure). When 
cochlear lesion ensues with destruction of the organ of 
Corti hair cells, hearing loss is irreversible8.
Amikacin, the first described aminoglycoside, is a 
derivative of kanamycin, active against most microbial 
species resistant to gentamicin and to kanamycin itself9.
The pattern of injury to the Organ of Corti involves 
the initial damage to the external hair cells on the basal 
turns of the cochlea, later progressing with a lesser degree 
of cochlear lesion, towards the cochlear apex10. The lesions 
affect preferably the outer hair cells, initially reaching the first 
row of cells, then following to the second and third rows11.
A dose of 400 mg/kg/day of intramuscular amikacin 
for 12 days causes the complete destruction of outer hair 
cells and a partial lesion to the internal ones, on the first 
and second turns of the cochlea of guinea pigs, with lesser 
lesions on the third and fourth turns10.
Non-damaging sound stimuli (low intensity ones), 
employed during a long period of time prior to the exposu-
re to traumatic noise of the same type, protect the cochleas 
of lab animals, reducing the physiological alterations and 
the lesions to the sensorial cochlear cells12, a phenomenon 
known as resistance. It is very likely that the conditioning 
stimuli would change the cell, making it more capable of 
withstanding damaging stimuli and the protection seems 
to be mediated by cochlear changes13.
It has been proved that the resistance phenome-
non is also manifested after the prior and longstanding 
administration of non-damaging doses of amikacin before 
employing the ototoxic doses, in other words, the non-
-damaging dose of amikacin significantly protects the hair 
cells against the ototoxicity of amikacin itself on the two 
most basal turns14.
Our goal has been to study the otoprotection of the 
outer hair cells against the ototoxicity caused by amikacin 
is temporarily persistent.
METHOD
We utilized fourteen albino lab animals (Cavia 
porcellus), weighing 250g and with the Preyer’s reflex. 
The study was approved by the Ethics Committee in ex-
perimentation with animals of our institution, approval 
protocols # 075/2008.
The drug utilized in this study was intramuscular 
amikacin. The Preyer’s reflex was tested daily, the same 
happened with the assessment of body weight until the 
maximum time before animal slaughtering.
The animals were distributed in three groups:
Group A (control) - Four guinea pigs injected with 
intramuscular distilled water for 30 days (two animals) and 
60 days (two animals).
Group B - Five animals injected with intramuscular 
amikacin 20 mg/kg/day, for 30 days (protective dose) and, 
afterwards, a dose of 400 mg/kg/day of amikacin (dama-
ging dose) for 12 days, the mean necessary time for the 
elimination of the Preyer’s reflex. After that, the animals 
were kept for 30 days on a regular diet, and they were 
afterwards slaughtered.
Group C - Five animals in the same amikacin ad-
ministration regimen from Group B were maintained for 
60 days and then slaughtered.
The technique used to study the histopathology 
changes in this study was the scanning electron microscopy 
(SEM), with attention to the structural damages caused to the 
Organ of Corti on the different cochlear turns, especially to the 
outer hair cells which received different doses of amikacin.
The guinea pigs were anesthetized by inhaling 
ether and then they were beheaded, their temporal bones 
containing their bullae were removed. The apex and the 
round window were opened and, for fixation, we used 
glutaraldehyde at 2.5% in a 0.1% phosphate buffer (So-
rensen) at 4°C. The microdissection carried out preserved 
the spiral lamina with the organ of Corti. This material was 
preserved for 12 hours in a 0.1M buffer solution, and it 
was reaffixed in an osmium tetroxide solution with 0.1M 
phosphate buffer for 1 hour at 4°C. The following stages 
were: dehydration in ethanol with drying using the critical 
point of liquid carbon dioxide in a BALTEC - CPD 030 - 
“CRITICAL POINT DRYER” device. The cochlear was then 
settled in a cylindrical specimen holder, fixed with carbon 
conductive paste and plated with gold (thin layer) through 
a vaporizer (BALTEC - SDC 050) for perfect visualization 
upon scanning electron microscopy.
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The auditory function of the animals was assessed 
by means of Distortion Product Otoacoustic Emissions 
(DPOAE) using the ILO 92 CAE System from Otodynamics 
LLC, with 70 dB SPL intensity of the triggering stimulus 
for F1 and F2, at a ratio of F1:F2 = 1.217. The DPOAE 
were studied out in the following situations: pre-exposure 
to amikacin, on the 15th day of administration of a non-
-damaging dose, at the end of the administration of the 
damaging dose and before slaughtering.
The DPOAE provide a functional comparison of 
the outer hair cells before and after the administration of 
the habituation dose and the damaging dose, providing 
information on the drug action on these cells during the 
entire period of the study, reducing the interference of 
the constitutional difference on the auditory function of 
each animal, enabling the true assessment of the action 
of amikacin on the outer hair cells.
RESULTS
All the animals in Group A had normal auditory 
function and histological pattern. (Figure 1A-D).
Figure 1. Example of DPOAE in group A. A: pre-exposure, we notice 
that the the auditory function is maintained, starting at 1 KHz, with the 
presence of DPOAE; B: After the non-damaging dose, showing the 
normal pattern with the presence of DPOAE; C: After the damaging 
dose, showing the presence of DPOAE; D: Example of SEM in the 
control group, showing normal inner and outer hair cells on the basal 
turn. 500x Magnification.
In Group B, the study of DPOAE showed a normal 
auditory function before exposure to the drug and 
maintenance of the pattern after the non-damaging dose 
(Figure 2A-B). Nonetheless, we see an important loss of the 
auditory function after the end of the administration of the 
damaging nose, proven by the lack of DPOAE (Figure 2C).
Figure 2. Example of DPOAE in Group B. A: pre-exposure, we notice 
that the auditory function was maintained, starting at 1 KHz, with the 
presence of DPOAE. B: DPOAE present after treatment with low, not 
damaging doses of amikacin. C: DPOAE present in all the tested 
frequencies after a damaging dose of 400 mg/kg/day of amikacin for 
12 days. D: Example of SEM in Group B, showing the destruction of 
outer hair cells on the basal turn. 750x magnification.
In the histology exam (Figure 2D), we noticed the 
cochlear involvement. The Organ of Corti clearly lost its 
support, showing a damage pattern which started on the 
basal turn - usually the most affected region, with total 
absence of outer hair cells and the presence only of the 
inner hair cells - a pattern that is maintained in the E2 turn. 
On the E3 turn, the inner hair cells and the first and second 
rows of outer hair cells were the most affected, in such a 
way that we notice only the presence of cell extrusions in 
the row of inner hair cells and just a few intact cells on the 
third row of outer hair cells. On the apex turn, there are 
more intact cells on the 1st row of outer hair cells, besides 
a lack of cilia on the inner hair cells.
In Group C, the functional findings assessed by 
the DPOAE and the histology exam by means of the SEM 
showed results identical to those found on Group B.
DISCUSSION
The ototoxicity caused by aminoglycosides is one 
of the most common causes of preventable sensorineural 
hearing loss15.
The aminoglycosides have the capacity to interact 
with iron, generating an active metabolite that is capable of 
catalyzing the formation of ROS, which are highly reactive 
compounds, physiologically formed as a consequence of 
aerobic cell metabolism16. Among the main examples of 
ROS, we have the hydrogen peroxide and the hydroxyl, 
hydroperoxyl and superoxyde.
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Such compounds may cause changes to the DNA, 
protein inactivation and lipid peroxidation of cell mem-
branes. Despite such deleterious effects, these compounds 
are important for the body, because they also participate 
in the defense against pathogens17,18. Therefore, it is 
indispensable to have a cell defense system against the 
potentially noxious actions of ROS, made up of antioxi-
dant agents such as glutathione, catalase and superoxyde 
dismutase.
The co-administration of antioxidant agents to 
guinea pigs together with gentamicin yielded a reduction 
on the drug-induced hearing loss19.
CONCLUSION
The self-defense phenomenon was not maintained 
beyond a period of 30 to 60 days after the injection of 
damaging doses of amikacin (400 mg/kg/day).
Cochlear otoprotection against the ototoxicity 
of aminoglycosides is proven; however, its mechanism 
is still not completely clear. We know that it probably 
involves the action of anti-free radical agents, such as 
glutathione, which is capable of inactivating the active 
metabolite formed by the interaction of amikacin and iron, 
which was found in the inner ear. Thus, the intracochlear 
levels of glutathione would be increased when low 
doses are administered for long periods of time before 
the administration of a damaging dose, protecting the 
cochlear OHC14.
The goal of the present study was to assess whether 
the mechanisms responsible for otoprotection would be 
able to maintain cell defense for longer periods of time - 
30 and 60 days. We can not state whether the self-defense 
phenomenon could last for more than 60 days.
We concluded that the high levels of anti free radi-
cals which should protect the cochlea, were consumed 
during the period of time in which the animals were kept, 
thus generating a balance between the ROS (noxious 
agents) and the antioxidants (protective agents), allow-
ing the noxious actions of the formers on the Organ of 
Corti. This unbalance is added to the high serum levels 
of amikacin (nephrotoxic effect).
This result helps outline new ways to better under-
stand the phenomenon of self-defense, as intents to change 
the drug regimen, change the periods of administration 
of damaging doses or the periods of administration of the 
protective and damaging doses.
The attempt to better understand the cochlear self-
defense mechanisms and to better act on maintaining such 
mechanisms for longer periods of time, until the end of the 
toxic effects of circulating aminoglycosides aims at devel-
oping a clinical applicability in pharmacological therapies.
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